NatMed Pro - References

8955

Anderson KJ, Teuber SS, Gobeille A, et al. Walnut polyphenolics inhibit in vitro human plasma and LDL oxidation. J Nutr 2001;131:2837-42. View abstract.

10340

Barch DH, Rundhaugen LM, Stoner GD, et al. Structure-function relationships of the dietary anticarcinogen ellagic acid. Carcinogenesis 1996;17:265-9.. View abstract.

10342

Constantinou A, Stoner GD, Mehta R, et al. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutr Cancer 1995;23:121-30.. View abstract.

10343

Xu Y, Deng JZ, Ma J, et al. DNA damaging activity of ellagic acid derivatives. Bioorg Med Chem 2003;11:1593-6.. View abstract.

10344

Mullen W, Stewart AJ, Lean ME, et al. Effect of freezing and storage on the phenolics, ellagitannins, flavonoids, and antioxidant capacity of red raspberries. J Agric Food Chem 2002;508:5197-201.. View abstract.

11335

Priyadarsini KI, Khopde SM, Kumar SS, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 2002;50:2200-6. View abstract.

11460

Dell'Agli M, Parapini S, Basilico N, et al. In vitro studies on the mechanism of action of two compounds with antiplasmodial activity: ellagic acid and 3,4,5-trimethoxyphenyl(6'-O-aalloyl)-beta-D-glucopyranoside. Planta Med 2003;69:162-4. View abstract.

96294

Ertam I, Mutlu B, Unal I, Alper S, Kivçak B, Ozer O. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008;35(9):570-4. View abstract.

96295

Dahl A, Yatskayer M, Raab S, Oresajo C. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. J Drugs Dermatol. 2013;12(1):52-8. View abstract.

96296

Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol. 2005;47(4):449-54 View abstract.

96297

Le Donne M, Lentini M, Alibrandi A, et al. Antiviral activity of Ellagic acid and Annona Muricata in cervical HPV related pre-neoplastic lesions: A randomized trial. J Funct Food 2017;35:549-54.

96298

Liu Y, Yu S, Wang F, et al. Chronic administration of ellagic acid improved the cognition in middle-aged overweight men. Appl Physiol Nutr Metab. 2018;43(3):266-73. View abstract.

100720

Zhou B, Li Q, Wang J, Chen P, Jiang S. Ellagic acid attenuates streptozocin induced diabetic nephropathy via the regulation of oxidative stress and inflammatory signaling. Food Chem Toxicol. 2019;123:16-27. View abstract.

100933

Zhong C, Qiu S, Li J, et al. Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma. Phytomedicine. 2019;59:152921. View abstract.

106054

Serretta V, Berardinis E, Simonato A, et al. A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis. Urologia. 2021 Jun 2:3915603211022285. View abstract.

106319

Ghadimi M, Foroughi F, Hashemipour S, et al. Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes. Phytother Res 2021;35(2):1023-1032. View abstract.

106320

Kazemi M, Lalooha F, Nooshabadi MR, Dashti F, Kavianpour M, Haghighian HK. Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome. J Ovarian Res 2021;14(1):100. View abstract.

106321

Ghadimi M, Foroughi F, Hashemipour S, et al. Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial. Diabetol Metab Syndr 2021;13(1):16. View abstract.